Skip to content
Peptigraph home
Shop Peptides50% off*

How Mazdutide Works: Mechanism and Pharmacology

How Mazdutide works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
Class
GLP-1 / glucagon dual agonist
FDA status
Not approved
Investigational in the US (approved in China)
Routes studied
subcutaneous
Half-life
[pending]
by route, with source

How long it acts

No published half-life found for Mazdutide (PubMed search, 2 Oct 2026)

Receptors it acts on

The phase 3 abstract calls mazdutide a dual agonist of the glucagon-like peptide-1 and glucagon receptors.[4]

A diabetes trial describes it as a dual GCGR/GLP-1R agonist.[5]

The phase 1b study, which called it IBI362, set safety, tolerability and pharmacokinetics as its objectives.[6]

What was seen in people

The meta-analysis reports reduced HbA1c and fasting glucose with mazdutide in type 2 diabetes.[7]

The phase 3 weight trial reported beneficial effects on all prespecified cardiometabolic measures.[4]

Why it is given weekly

The US phase 2 trial gave once-weekly subcutaneous injections for 48 weeks.[8]

The evidence file records no half-life value for mazdutide, so the reason for weekly dosing is not stated in the cited papers; the phase 1b study lists pharmacokinetics as an objective but gives no number.

Calculated from evidence file web/src/data/evidence/mazdutide.json; half life values 0. Formula: half-life values found = 0

Common questions

How long does Mazdutide act in the body?

We found no published half-life for Mazdutide (PubMed search, 2 Oct 2026), so how long it acts is unknown.

Is mazdutide a GLP-1?

It is a dual GLP-1 and glucagon receptor agonist rather than a GLP-1-only drug.[4]

More on Mazdutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.For diabetesWhat research says about Mazdutide for diabetes.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
  5. 5Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
  6. 6IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
  7. 7Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2024PMID 38440786Accessed 2 Oct 2026
  8. 8Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026

Found an error? Report a correction.